



Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

CAMBRIDGE, Mass., Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.

Leap Presentation Details:

Piper Sandler 36th Annual Healthcare Conference

Date: Wednesday, December 4, 2024

Time: 4:00 p.m. Eastern Time

A live webcast of the fireside chat may be accessed on the Investors page of the company's website at <https://investors.leaptx.com/>, where a replay of the events will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit <http://www.leaptx.com> or view our public filings with the SEC that are available via EDGAR at <http://www.sec.gov> or via <https://investors.leaptx.com/>.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-302313181.html>

SOURCE Leap Therapeutics, Inc.